Patients accept therapy using embryonic stem cells for Parkinson’s disease: a discrete choice experiment

BMC Medical Ethics

Research

Jennifer Drevin¹  Mats Hansson¹  Jorien Veldwijk²  Jennifer Viberg Johansson³  Elena Jiltsova⁴  Dag Nyholm⁴  Trinette van Vliet⁵  Hakan Widner⁵  Catharina Groothuis-Oudshoorn⁶  Karin Schölin Bywall⁷ 

[1] Centre for Research Ethics and Bioethics, Uppsala University, Box 564, SE-751 22, Uppsala, Sweden;Centre for Research Ethics and Bioethics, Uppsala University, Box 564, SE-751 22, Uppsala, Sweden;Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands;Erasmus Choice Modelling Centre, Erasmus University Rotterdam, Rotterdam, The Netherlands;Centre for Research Ethics and Bioethics, Uppsala University, Box 564, SE-751 22, Uppsala, Sweden;The Institute for Future Studies, Holländargatan 13, 111 36, Stockholm, Sweden;Department of Medical Sciences, Uppsala University, Uppsala University Hospital, SE-751 85, Uppsala, Sweden;Department of Neurology, Skåne University Hospital, SE-221 85, Lund, Sweden;Health Technology and Services Research (HTSR), Faculty of Behavioural Management and Social Sciences, University of Twente, Enschede, The Netherlands;School of Health, Care and Social Welfare, Division of Health and Welfare Technology, Mälardalen University, Västerås, Sweden;Centre for Research Ethics and Bioethics, Uppsala University, Box 564, SE-751 22, Uppsala, Sweden;

关键词: Ethics;    Human embryonic stem cells;    Parkinson’s disease;    Patient preferences;   

DOI  :  10.1186/s12910-023-00966-1

 received in 2023-03-17, accepted in 2023-10-03,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundNew disease-modifying ways to treat Parkinson’s disease (PD) may soon become a reality with intracerebral transplantation of cell products produced from human embryonic stem cells (hESCs). The aim of this study was to assess what factors influence preferences of patients with PD regarding stem-cell based therapies to treat PD in the future.MethodsPatients with PD were invited to complete a web-based discrete choice experiment to assess the importance of the following attributes: (i) type of treatment, (ii) aim of treatment, (iii) available knowledge of the different types of treatments, (iv) effect on symptoms, and (v) risk for severe side effects. Latent class conditional logistic regression models were used to determine preference estimates and heterogeneity in respondents’ preferences.ResultsA substantial difference in respondents’ preferences was observed in three latent preference patterns (classes). “Effect on symptoms” was the most important attribute in class 1, closely followed by “type of treatment,” with medications as preferred to other treatment alternatives. Effect on symptoms was also the most important attribute in class 2, with treatment with hESCs preferred over other treatment alternatives. Likewise for class 3, that mainly focused on “type of treatment” in the decision-making. Respondents’ class membership was influenced by their experience in treatment, side effects, and advanced treatment therapy as well as religious beliefs.ConclusionsMost of the respondents would accept a treatment with products emanating from hESCs, regardless of views on the moral status of embryos. Preferences of patients with PD may provide guidance in clinical decision-making regarding treatments deriving from stem cells.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 4

Fig. 1